This open label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Actemra at a dose of 8 mg/kg intravenously every 4 weeks for 24 weeks (6 infusions).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01610791?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
